Santen, Sydnexis reach licensing agreement for atropine formulation
Santen and Sydnexis have finalized an exclusive licensing agreement for SYD-101 in Europe, Middle East and Africa for the treatment of progressive childhood myopia, according to a press release.
SYD-101 (atropine sulfate ophthalmic solution 0.01% and 0.03%, Sydnexis) is an investigational formulation that is being evaluated in the phase 3 STAAR study in the United States and Europe, the release said.
“We are excited to partner with Santen, a global leader in ophthalmology, to help fulfill our goal of making SYD-101 available in EMEA. We recognize the expertise that Santen brings to the table in understanding and navigating the registration process in the EMEA region and look forward to collaborating with Santen in addressing the myopia needs in these broader geographic regions,” Kenneth Widder, CEO of Sydnexis, said in the release.
The low-dose formulation of atropine is proprietarily formulated to be “pharmacologically stable without needing to lower the pH in order to achieve a shelf life of up to 3 years at room temperature,” the release said.